Farmeconomia. Health economics and therapeutic pathways <p>eISSN: 2240-256X<br />h5-index:7<br /><br /></p><p><em>Farmeconomia. Health Economics and Therapeutic Pathways</em> publishes original researches and reviews in pharmacoeconomics and health economics. It is indexed in:</p><ul><li><a href=";publication=Farmeconomia.+Health+economics+and+therapeutic+pathways" target="_blank">CrossRef</a></li><li><a href="" target="_blank">DOAJ</a> – Directory of Open Access Journals</li><li><a href="" target="_blank">Emerging Sources Citation Index</a> (ESCI)</li><li><a href=";q=farmeconomia&amp;hl=it&amp;as_sdt=0,5" target="_blank">GoogleScholar<br /></a></li><li><a href="" target="_blank">OpenAIRE</a></li><li><a href="" target="_blank">SHERPA/RoMEO</a></li></ul><p>The aim is to provide contents of the highest quality, authority and accessibility. Emphasis is placed on evaluation of new drugs and pharmacoeconomics models, but the journal also publishes economic analysis of all types of healthcare interventions and of health policy initiatives, evaluation of methodologies, and analysis of pricing and reimbursement systems. Readership includes health economists, market access experts, and in general everyone who has an interest in pharmacoeconomics, health economics, health policy, and public health.<br />Contents are subject to double-blind <a href="/index.php/FE/about/editorialPolicies#peerReviewProcess" target="_blank">peer review process</a> and are editorially independent. <br /><em>Farmeconomia. Health Economics and Therapeutic Pathways</em> is an <a href="/index.php/FE/about/editorialPolicies#custom-0">open access</a> journal that provides immediate open access to all of its articles (both HTML and PDF versions) on the principle that making research freely available to the public supports a greater global exchange of knowledge.</p> en-US <p>Authors who publish with this journal agree to the following terms:</p><ol type="a"><li>Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a <a href="" rel="license" target="_blank">Creative Commons Attribution-NonCommercial 4.0 License</a> that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.</li><li>Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. The Publication Agreement can be downloaded <a href="/index.php/FE/manager/files/repository/PublishingagreementFE.pdf" target="_blank">here</a>, and should be signed by the Authors and sent to the Publisher when the article has been accepted for publication in this journal.</li><li>Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (see <a href="" target="_blank">The Effect of Open Access</a>).</li><li>Authors are permitted to post their work online after publication (the article must link to publisher version, in html format)</li></ol> (Ombretta Bandi) (Gisella Alberigo) Mon, 28 Jan 2019 09:48:41 +0000 OJS 60 Economic Evaluation of Different Organizational Models for the Management of Patients with Hepatitis C <p class="abstract">BACKGROUND: Access to Directly Acting Antivirals (DAAs) for Hepatitis C Virus (HCV) treatment in Italy was initially restricted to severe patients. In 2017, AIFA expanded access to all patients, to achieve elimination by 2030.</p><p class="abstract">AIM: To investigate the impact of different hospitals’ organizational models on elimination timing, treatment capacity and direct costs.</p><p class="abstract">METHODS: Most Regional healthcare systems in Italy deploy a Center of Excellence (CoE) organizational model, where patients are referred to a single major hospital in the area, which is the only one that can prescribe and deliver DAAs. The study was conducted at Bergamo’s (Lombardy, Italy) Papa Giovanni XXIII hospital (PG-23), which deploys a Hub&amp;Spoke model: the Hub (PG-23) prescribes and delivers DAAs while Spokes (four smaller hospitals) can only prescribe them. The study compares the two models (CoE vs. H&amp;S). Patient journey and workloads were mapped and quantified through interviews with hospital stakeholders. Cost data were collected through the hospital’s IT system; the sample comprised 2,277 HCV patients, over one year.</p><p class="abstract">RESULTS: The study calculated the average cost to treat HCV patients (~ € 1,470 per patient). Key cost drivers are lab tests (60%) and specialist visits (30%). Over one year, H&amp;S can treat 68% more patients than CoE. As deferred patients absorb up to 40% of total costs, the “Optimized” model was designed by streamlining specialists’ visits and involving general practitioners during follow-up. “Optimized” model increases treatment capacity and reduces costs of deferred patients by 72% vs CoE.</p><p class="abstract">CONCLUSION: The study demonstrates the importance of organizational models in efficiently achieving 2030 elimination.</p> Stefano Fagiuoli, Luisa Pasulo, Franco Maggiolo, Rosaria Spinella, Paolo Del Poggio, Roberto Boldizzoni, Mariella Di Marco, Alessandro Aronica, Chiara Benedetti, Paolo Correale, Chiara Garavaglia, Carlo Nicora Copyright (c) 2019 Stefano Fagiuoli, Luisa Pasulo, Franco Maggiolo, Rosaria Spinella, Paolo Del Poggio, Roberto Boldizzoni, Mariella Di Marco, Alessandro Aronica, Chiara Benedetti, Paolo Correale, Chiara Garavaglia, Carlo Nicora Mon, 28 Jan 2019 09:48:41 +0000 Erratum: Effectiveness of Long-Acting Injectable Antipsychotics in Schizophrenia: A Literature Review and Bayesian Meta-Analysis Informing Economic Considerations <p>There was an error in the relapse rate reduction reported in Figure 2 in this article by Zaniolo et al. [<em>Farmeconomia. Health economics and therapeutic pathways</em> 2019; 20: 13-24; <a href=""></a>]. The online version has been corrected on 13 February 2019.</p> [No authors listed] Copyright (c) 2019 No authors listed Wed, 13 Feb 2019 10:55:59 +0000 Prova Provetta7 <p>dgcdfgi</p> Mario Pinotti Copyright (c) 2019 Gino Panino Tue, 16 Apr 2019 00:00:00 +0000 Effectiveness of Long-Acting Injectable Antipsychotics in Schizophrenia: A Literature Review and Bayesian Meta-Analysis Informing Economic Considerations <p class="abstract">BACKGROUND: Although the use of long-acting injectable antipsychotics (LAIs) is considered an important option in the management of schizophrenia two recent meta-analysis, which aimed to compare LAIs vs oral antipsychotics (OAPs) in terms of relapse rate, showed discordant results.</p> <p class="abstract">AIM: To investigate factors affecting the efficacy of antipsychotics in terms of relapse prevention in the real-world and to estimate the management cost of an episode of relapse.</p> <p class="abstract">METHODS: We conducted a literature search using MEDLINE/PubMed with the aim to extract efficacy, effectiveness and adherence data of LAIs and OAPs. The primary outcome was the relative risk (RR) of relapse between two strategies. The extracted RR were included in a series of Bayesian statistical models based on the starting hypotheses. The RR rates obtained from the meta-analysis have been used as input for an economic evaluation of the total costs associated with the management of the patient with schizophrenia from the Italian NHS perspective.</p> <p class="abstract">RESULTS: The literature search identified 34 studies which met the inclusion criteria and were analyzed. According to the model that best explains the data, in the real-world setting the effectiveness with LAIs is greater than with OAPs, with a more pronounced effect for SGAs than for FGAs. Taking into account generation, route and frequency of administration, the RR decreased with lower administration frequency, with SGA LAI administered once every 90 days which is associated with the greatest reduction in the risk of relapse (-85%). When the results of the meta-analysis are used to feed an economic evaluation the results show that the SGA administered every 90 days is the strategy with the least expected cumulative cost both at 1 (€ 3,509) and 5 years (€ 19,690).</p> <p class="abstract">CONCLUSION: SGA LAIs administered every 90 days seems to be the best option for the treatment of patient with schizophrenia from both the clinical and economic perspectives.</p> <p class="abstract"><span class="st">&nbsp;</span></p> <p class="abstract"><span class="st">An erratum to this article is available online at:&nbsp;<a href="" target="_blank" rel="noopener"></a></span></p> Orietta Zaniolo, Gianni Ghetti, Massimiliano Povero, Lorenzo Pradelli Copyright (c) 2019 Orietta Zaniolo, Lorenzo Pradelli Wed, 13 Feb 2019 10:54:20 +0000